AAN 2025: Lundbeck highlights sustained efficacy of Vyepti for migraine prevention
Post hoc analysis of the long-term, open-label Phase III PREVAIL (NCT02985398) study evaluating two-year safety and patient-reported outcomes with Vyepti in adults with chronic migraine was presented in a poster at AAN 2025. The analysis showed that the majority of the participants who achieved 50% or greater headache response or 75% or greater headache response in the first 12 weeks after receiving their first dose of Vyepti were able to maintain that level of response up to Week 84. Sustained treatment response was further demonstrated in another poster presenting post hoc analysis of data from the randomized, placebo-controlled Phase III DELIVER (NCT04418765) trial. In this study, patients had either chronic migraine or high-frequency episodic migraine, and they had failed to respond to two to four prior migraine preventive treatments. Up to 83% of patients who responded to Vyepti treatment within the first one to 24 weeks of the trial (i.e., having received the first two doses of Vyepti) were able to maintain that response over the 72-week trial. These analyses highlight that early treatment response with Vyepti may be able to predict long-term sustained treatment response.
A third poster focused on patient-reported impact of Vyepti treatment in adults with chronic migraine. It presented a post hoc analysis of the impact of a 75% or greater increase in good days/month in patients treated with Vyepti from a real-world, observational, US-based study. Approximately two-thirds of the patients in the study reported a 75% or greater increase in good days/month, and this was correlated with higher satisfaction regarding the effects of Vyepti on migraine symptom severity, frequency, and duration; daily activities, such as being able to participate in social/family life, being productive, and ability to plan; and overall wellbeing when compared with patient with less than 75% increase in good days/month. Prior to treatment, the prevalence of brain fog was similar across the treatment response subgroups; however, following Vyepti treatment, 76.6% of the patients with a 75% or greater increase in good days/month reported moderate-to-complete
improvement in brain fog, compared with 42.3% of patients with less than 75% increase in good days/month. These results highlight the meaningful benefits that patients experience following Vyepti treatment and will help Lundbeck with its focus on 'raising the bar around preventive treatment expectations in migraine.'
Historically, migraine prevention has been managed with a wide variety of drug classes, such as beta-adrenergic receptor blockers, calcium antagonists, antidepressants, and anti-epileptics. However, many of these oral preventive treatments have been associated with poor side-effect profiles, and KOLs previously interviewed by GlobalData reported that low efficacy of oral preventive treatment was common among patients, meaning that patients often cycle through the different drug classes of oral preventive treatments. The first preventive therapies developed specifically for the treatment of migraine were the anti-CGRP mAbs, followed by the oral gepants; however, they are typically prescribed as second- or third-line options for many patients due to reimbursement restrictions requiring failure with the oral preventives before they can be prescribed.
In the US, a 2024 statement was published by the American Headache Society recommending that the anti-CGRP mAbs and gepants should be used as first-line preventive options due to their superior efficacy and tolerability compared with the oral preventive options. Long-term sustained efficacy data and demonstration of meaningful benefit for patients, such as was presented for Vyepti at AAN 2025, are likely to further cement the case for first-line adoption of the anti-CGRP mAbs; however, given the comparative costs of the oral preventives and the mAbs, whether this recommendation will be implemented by insurance companies remains to be seen.
Vyepti faces significant competition from three other anti-CGRP mAbs: Amgen's Aimovig (erenumab), Eli Lilly's Emgality (galcanezumab), and Teva's Ajovy (fremanezumab). Additional competition also comes from two orally administered gepants: Pfizer's Nurtec (rimegepant) and AbbVie's Qulipta (atogepant). KOLs agreed that the CGRP mAbs had similar efficacy profiles, with treatment choice often based on side effects, dosing schedule, or patient preference. As the only intravenously administered mAb, Vyepti may be at a disadvantage among patients who prefer to self-administer one of the other mAbs, and therefore highlighting the long-term efficacy, particularly with a focus on some of the patient-reported meaningful benefits, will be crucial in helping Vyepti to remain competitive in the migraine prevention market.
"AAN 2025: Lundbeck highlights sustained efficacy of Vyepti for migraine prevention" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
United States Epilepsy Drugs Market Trends and Company Analysis Report 2025-2033 Featuring Eisai, UCB, H. Lundbeck, GW Pharmaceuticals, Abbott, Alkem Laboratories, Bausch Health, GSK
The United States Epilepsy Drugs Market is projected to grow from US$ 2.36 billion in 2024 to US$ 3.45 billion by 2033, marking a CAGR of 4.31% from 2025 to 2033. This growth is fueled by the rising prevalence of epilepsy, affecting over 3.4 million Americans, and advancements in drug development. Key players like Eisai, UCB, and Lundbeck emphasize second and third-generation AEDs offering improved safety and efficacy. Despite challenges like high treatment costs and regulatory hurdles, the market benefits from supportive FDA policies. Segmentation includes first, second, and third-generation drugs across various seizures and distribution channels. U.S. Epilepsy Drugs Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "United States Epilepsy Drugs Market - Therapeutic Landscape & Forecast 2025-2033" report has been added to States Epilepsy Drugs Market is expected to reach US$ 3.45 billion by 2033 from US$ 2.36 billion in 2024, with a CAGR of 4.31% from 2025 to 2033 In order to satisfy shifting customer needs, firms are being prompted by this transition to innovate and diversify their product lines. All things considered, the market for French-flavored milk is expected to grow further due to innovation, custom, and customer preferences. The market for epilepsy medications in the United States is a vibrant area of the larger neurology therapeutics business, with a wide range of antiepileptic medications (AEDs) that target different kinds of seizures. North America accounted for the greatest portion of the worldwide market for epilepsy medications in 2024, with the United States leading the way in terms of market size and revenue production. Due to their enhanced safety profiles and effectiveness, second-generation AEDs are growing at the quickest rate in the market, which is divided into first, second, and third-generation AEDs. The high demand for efficient treatment solutions is shown by the estimated 1.2% prevalence of epilepsy in the United prevalence of epilepsy has increased in the U.S. population. The seizures Foundation estimates that more than 3.4 million Americans suffer from seizures. Furthermore, 1 in 26 Americans are predicted to receive a diagnosis of epilepsy at some point in their lives, with over 150,000 receiving a diagnosis each year. New developments in medication development have accelerated the market's growth even further. The FDA's 2022 approval of ganaxolone (Ztalmy) for the treatment of seizures linked to CDKL5 deficient condition was a noteworthy milestone that provided a new therapeutic option for a patient population that had previously been underserved. Furthermore, the growing investment in specialist epilepsy medicines is demonstrated by Lundbeck's $2.6 billion acquisition of Longboard Pharmaceuticals in 2024, which was intended to develop bexicaserin for the treatment of developmental and epileptic encephalopathies. These advancements are in line with the demand for treatments that target complicated and uncommon epilepsy disorders as well as the increased emphasis on customized Factors Driving the United States Epilepsy Drugs Market Growth Increasing Prevalence of EpilepsyOne of the main factors propelling market growth is the increasing prevalence of epilepsy in the United States. It affects around 2.9 million individuals who are 18 years of age or older, with a significant incidence in youngsters. The need for efficient anti-epileptic medications (AEDs) is increased by this expanding patient base. Certain demographics, such as those from minority racial and ethnic groups and those with lower educational attainment, are more likely to have the syndrome. As more people look for medical intervention and treatment alternatives, the market is growing as a result of growing awareness and diagnosis of epilepsy. In order to satisfy the needs of a varied patient population, this trend emphasizes the necessity of ongoing innovation and accessibility in the creation and distribution of in Drug DevelopmentSecond and third-generation anti-epileptic medications (AEDs), which have better effectiveness and safety profiles, have been introduced as a result of ongoing research and development efforts. These more recent drugs aim to overcome the drawbacks of previous therapies by improving seizure control while reducing adverse effects. These developments not only improve patient outcomes but also provide medical professionals more treatment alternatives. The dedication to meeting the unmet requirements of the epilepsy community is seen in the ongoing pipeline of new AEDs, which propels market Regulatory EnvironmentFaster access to new medicines is made possible by the U.S. Food and Drug Administration's (FDA) accelerated approval of innovative anti-epileptic medications (AEDs). Pharmaceutical firms are encouraged to invest in the discovery of novel medicines by this regulatory assistance. Furthermore, programs like the Epilepsy Foundation's #RemoveTheFilter and National Epilepsy Awareness Month have raised public awareness and decreased stigma, which has encouraged more people to seek treatment. Because of these initiatives, the patient population is more informed, which increases the likelihood of diagnoses and treatment compliance. The market for epilepsy medications is expected to develop in a favorable environment because to a mix of supportive regulatory frameworks and increased public in the United States Epilepsy Drugs Market High Treatment Costs and Affordability IssuesAccess to therapy is severely hampered by the rising costs of antiepileptic medications (AEDs) in the US. For example, generic drugs are frequently less expensive than name-brand ones, such as Fycompa and Aptiom, which may cost thousands of dollars a month. Generics are not always readily available, and some more recent AEDs do not have generic counterparts, which keeps their prices high. Furthermore, insurance coverage might vary; Medicare seniors are frequently not eligible for co-pay assistance programs, and other plans have hefty deductibles or co-pays. These monetary difficulties may cause patients to stop taking their medications, which raises the risk of seizures and related problems. In order to provide fair access to efficient epilepsy therapies, it is imperative that these economic concerns be Hurdles and Market Entry DelaysNew antiepileptic medications (AEDs) must pass rigorous regulatory criteria enforced by the U.S. Food and Drug Administration (FDA), which include thorough documentation and lengthy clinical studies. For pharmaceutical firms, this stringent procedure may raise development costs and postpone the release of new medications. Furthermore, generic versions of important AEDs are introduced when their patents expire; although they are less expensive, they might not always satisfy the unique demands of every patient. People who need specialized care may have fewer alternatives due to these market factors. Additionally, market access and the profitability of AED development initiatives may be hampered by the drawn-out and expensive approval procedures linked to regulatory obstacles. Company Analysis: Overview, Key Persons, Recent Developments, Revenue Analysis Eisai Co., Ltd. UCB Inc. H. Lundbeck A/S GW Pharmaceuticals Plc. Abbott Laboratories Alkem Laboratories Limited Bausch Health Companies Inc. GSK plc Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $2.36 Billion Forecasted Market Value (USD) by 2033 $3.45 Billion Compound Annual Growth Rate 4.3% Regions Covered United States Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.2 Research Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Exploring the Disease - Background and Key Insights5.1 Introduction5.2 Causes5.3 Classification of Epilepsies5.3.1 West Syndrome5.3.2 Dravet syndrome5.3.3 Lennox-Gastaut syndrome5.3.4 Landau-Kleffner syndrome5.3.5 Epilepsy with continuous spike-and-waves during slow-wave sleep (ECSWS)5.3.6 CDKL5 deficiency disorder (CDD)5.4 Risk Factors5.5 Pathophysiology5.6 Diagnosis5.6.1 Diagnostic Guidelines5.6.1.1 NICE: Epilepsies in Children, Young People, and Adults (2022)5.6.1.2 American Family Physician: Diagnostic Evaluation (2017)5.6.1.3 The French National Authority for Health (HAS): 20205.6.1.4 German Society for Neurology (DGN) Guidelines: Diagnostics and Therapy in Neurology (2023)5.7 Treatment5.7.1 Antiepileptic Medications (AEDs)5.7.2 Receptor Blockers5.7.3 Others5.7.4 Diet Therapy5.7.5 Surgery5.7.5.1 Phase I Evaluation (Noninvasive Tests)5.7.5.2 Phase II Evaluation (Invasive Mon)5.7.6 Treatment Algorithm for Medical Condition5.7.7 Treatment Guidelines5.7.7.1 American Epilepsy Society5.7.7.2 American Family Physician - Epilepsy Treatment Options (2017)5.7.7.3 The International League against Epilepsy (ILAE) Epilepsy Guidelines5.7.7.4 NICE Guidelines: (2022)5.7.8 Living and Coping with Epilepsy6. United States Epilepsy Drugs Market6.1 Historical Market Trends6.2 Market Forecast7. Market Share Analysis7.1 By Drugs Category7.2 By Seizure types7.3 By Distribution Channels8. Drugs Category8.1 First Generation Drugs8.2 Second Generation Drugs8.3 Third Generation Drugs9. Seizure Types9.1 Focal Seizures9.2 Generalized Seizures9.3 Non-Epileptic Seizures10. Distribution Channels10.1 Hospital Pharmacies10.2 Drug Stores and Retail Pharmacies10.3 Online Providers11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Rivalry11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threat13. Analysis of Marketed Medications/Drugs13.1 Key Players13.2 EPIDIOLEX/EPIDYOLEX (cannabidiol) - Jazz Pharmaceuticals13.2.1 Description of Drugs13.2.2 Regulatory Milestones13.2.3 Clinical Development Process13.2.4 Safety and Efficacy13.3 XCOPRI/ONTOZRY(cenobamate) - SK Biopharmaceutical/ Pharma/Ono Pharmaceutical13.4 FINTEPLA (fenfluramine) - UCB/Nippon Shinyaku13.5 NAYZILAM (midazolam) nasal spray - UCB Pharma13.6 VALTOCO (diazepam nasal spray) - Neurelis/Aculys Pharma13.7 ZTALMY (ganaxolone) - Marinus Pharmaceuticals/Ovid Therapeutics/Orion13.8 BRIVIACT/NUBRIVEO (brivaracetam) - UCB Pharma13.9 FYCOMPA (perampanel) - Eisai/Catalyst Pharmaceutical13.10 OXTELLAR XR (oxcarbazepine) - Supernus Pharmaceuticals13.11 VIMPAT (lacosamide) - UCB Pharma/Daiichi Sankyo14. Analysis of Emerging Drugs14.1 Key Cross Competition14.2 XEN1101 - Xenon Pharmaceuticals14.2.1 Description of Drug14.2.2 Clinical Research & Development14.2.3 Safety and efficacy14.3 LIBERVANT (diazepam buccal film) - Aquestive Therapeutics/Atnahs Pharma (Pharmanovia)14.4 Soticlestat (TAK-935) - Takeda/Ovid Therapeutics14.5 COMFYDE (carisbamate) - SK Biopharmaceuticals (SK Life Science)14.6 BHV-7000 (KB-3061) - Biohaven Pharmaceuticals/Knopp Biosciences14.7 STACCATO alprazolam (benzodiazepine) - UCB Pharma/Alexza Pharmaceuticals14.8 NBI-827104 (ACT-709478) - Neurocrine Biosciences/Idorsia Pharmaceuticals14.9 Ivermectin (EQU-001) - Equilibre Biopharmaceuticals15. Regulations and Reimbursement Policies16. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Epilepsy Drugs Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
05-08-2025
- Yahoo
Denmark Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring Novo Nordisk, H. Lundbeck, Leo, Orifarm, ALK-Abell, Xellia, Takeda, Sandoz, Ferring Pharmaceuticals, FUJIFILM
Denmark's pharmaceutical market is projected to grow from US$ 3.81 billion in 2024 to US$ 5.20 billion by 2033, with a CAGR of 3.52%. Key drivers include advanced health data infrastructure, supportive government policies, heavy R&D investment, and contributions from pharmaceutical giants like Novo Nordisk and Lundbeck. The aging population, rise in chronic diseases, and demand for innovative treatments further fuel growth. However, challenges such as regulatory complexity and sustainability pressures persist. The market encompasses a wide range of therapeutic classes and distribution channels, making Denmark a competitive hub for pharmaceutical R&D and innovation. Danish Pharmaceutical Market Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Denmark Pharmaceutical Market - Drug Development & Forecast 2025-2033" report has been added to Pharmaceutical Market is expected to reach US$ 5.20 billion by 2033 from US$ 3.81 billion in 2024, with a CAGR of 3.52% from 2025 to 2033 Heavy R&D spending, government assistance, well-developed healthcare system, aging population, growth in the incidence of chronic diseases, advances in biotechnology, world demand for exports, and the location of world-class pharmaceutical giants such as Novo Nordisk and Lundbeck are all determinants of Denmark's expanding pharmaceutical market. Investigation, research, production, and promotion of drugs and therapies utilized to cure, prevent, or control disease fall within the pharmaceutical sector. Through the provision of innovative medical treatments and increased life expectancy and quality of life, it plays an important role in world medicine. Scientific breakthroughs, government approvals, and the ongoing demand for effective treatments drive this industry. Both small biotech firms and international corporations are prominent players. Prescription drugs, vaccines, and over-the-counter drugs are all pharmaceuticals. The sector often collaborates with research and clinical institutions to accelerate development and is highly regulated to ensure safety and efficacy of R&D expenditures, a collaborative academic and health environment, and supportive government regulations are the primary impetus for Denmark's pharmaceutical industry. Major contributions are made by leading global companies such as Novo Nordisk and Lundbeck through specialty medicine creation and global exports. Demand within the domestic market is also boosted by an aging population and the spread of chronic diseases such as diabetes. Innovation through personalized therapy and real-world evidence creation are enabled by advanced health data infrastructure in Denmark. Its global competitiveness is enhanced by an open regulatory system and access to EU markets. These combine to offer a robust, future-proof pharmaceutical sector with scope to Drivers for the Denmark Pharmaceutical Market Advanced Health Data InfrastructureOne of the key drivers for Denmark's pharmaceutical market's growth is its advanced heath data infrastructure. With biobanks, illness registries, and population-level electronic health records, the country boasts one of the most advanced and unified systems of healthcare data in the world. Since every Danish citizen is assigned a personal identification number, medical records can be exactly correlated between clinics, hospitals, and pharmacies. The approach opens up real-world data to academics and pharma companies to facilitate post-marketing surveillance, drug development, and clinical trials. Such access reduces the cost and time-to-market of research as well as speeds up pharmacovigilance and personalized treatment innovation. It also enhances the quality and efficiency of clinical trials by enabling long-term follow-up and targeted patient recruitment. In addition, Denmark is a safe destination for international collaboration due to the stringent data protection legislation that ensures patient confidentiality. This technological advantage enhances Denmark's competitiveness in the life sciences world and makes it a leading site for pharmaceutical R& Government PoliciesDenmark's pharma industry is growing largely due to the favorable government policies of the country. Denmark has established a comprehensive Life Sciences Growth Plan incorporating 36 initiatives across six key areas such as clinical trials, R&D, and regulatory environments. This strategic plan aims to further consolidate Denmark's reputation as a leading life sciences nation by fostering innovation and streamlining establishment of a "one-stop-shop" for drug companies that simplifies and quickens the regulatory approval process is an essential component of this program. By reducing administrative barriers, this program makes it easier for businesses to set up and expand production sites in Denmark. In addition, Denmark's climate agreement with the pharmaceutical industry illustrates its commitment to environmental responsibility. Consistent with international environmental aims, our partnership works to support green innovation and reduce CO2 emissions. Overall, taken as a package, all these beneficial government programs offer a good environment for pharmaceutical companies to expand, innovate, and become globally competitive for Denmark's pharmaceutical R&D InvestmentHigh investment in research and development (R&D) is one of the factors propelling the growth of the pharmaceutical market in Denmark. With a significant proportion being allocated to life sciences and pharmaceuticals, the country has some of the highest R&D expenditures per GDP of any nation globally. Both the public funding of the Danish government and substantial contributions from the private sector - particularly from major players such as Novo Nordisk and Lundbeck - funding this hospitals, and enterprise are in close collaboration to facilitate Denmark's R&D environment that encourages innovation in biotechnology, personalized medicine, and drug development. Tax reductions, subsidies, and strategic initiatives such as the Life Sciences Growth Plan are some of the government measures that actively encourage R&D. Contemporary research infrastructure and highly skilled staff are also available, which adds to Denmark's competitive edge. This robust R&D climate accelerates the development of novel treatments, attracts foreign partnerships, and makes Denmark a world leader in clinical excellence and pharmaceutical in the Denmark Pharmaceutical Market Regulatory Complexity and EU ComplianceEU compliance and regulatory complexity provide major obstacles for Denmark's pharmaceutical industry. Businesses have to deal with two sets of regulations: strict European Union guidelines and Danish state laws. This results in a complicated and frequently drawn-out approval process for new medications and clinical studies, which can raise expenses and postpone market entry. Startups and small and medium-sized businesses (SMEs) frequently find it difficult to satisfy these standards due to the resource requirements and administrative load. Furthermore, ongoing adaptation is necessary due to the EU's periodic revisions and harmonization initiatives. For Danish pharmaceutical businesses, sustaining innovation speed while balancing compliance is still a major and Green TransitionFor Denmark's pharmaceutical industry, sustainability and the green transition pose increasing obstacles. There is growing pressure on the business to lessen its environmental impact, which includes controlling water use in manufacturing processes, cutting carbon emissions, and limiting waste. Significant investments in cleaner technologies and process innovations are necessary to meet Denmark's aggressive climate targets and EU environmental requirements. Pharmaceutical businesses also need to strike a balance between sustainability measures and preserving cost-effectiveness and production efficiency. Changes in sourcing procedures and supply networks are also necessary for this shift. The Danish pharmaceutical industry must overcome the difficult task of successfully incorporating green practices while maintaining its competitiveness in order to keep up with worldwide sustainability trends. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, SWOT Analysis, Sales Analysis Novo Nordisk A/S H. Lundbeck A/S Leo Pharma A/S Orifarm Group A/S ALK-Abell A/S Xellia ApS Takeda Pharma A/S Sandoz A/S Ferring Pharmaceuticals A/S FUJIFILM Diosynth Biotechnologies Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $3.81 Billion Forecasted Market Value (USD) by 2033 $5.2 Billion Compound Annual Growth Rate 3.5% Regions Covered Denmark Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Denmark Pharmaceutical Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Therapeutic Class6.2 By Drug Type6.3 By Prescription Type6.4 By Distribution Channel7. Therapeutic Class7.1 Cancer7.1.1 Market Analysis7.1.2 Market Size & Forecast7.2 Infectious Diseases7.3 Cardiovascular Diseases7.4 Diabetes7.5 Respiratory Diseases7.6 Central Nervous System Disorders7.7 Autoimmune Diseases7.8 Others8. Drug Type8.1 Branded8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Generic9. Prescription Type9.1 OTC Drugs9.1.1 Market Analysis9.1.2 Market Size & Forecast9.2 Prescription Drugs10. Distribution Channel10.1 Hospital Pharmacy10.1.1 Market Analysis10.1.2 Market Size & Forecast10.2 Retail Pharmacy10.3 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Novo Nordisk A/S14.2 H. Lundbeck A/S14.3 Leo Pharma A/S14.4 Orifarm Group A/S14.5 ALK-Abell A/S14.6 Xellia ApS14.7 Takeda Pharma A/S14.8 Sandoz A/S14.9 Ferring Pharmaceuticals A/S14.10 FUJIFILM Diosynth Biotechnologies15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Danish Pharmaceutical Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Bloomberg
18-07-2025
- Bloomberg
Otsuka, Lundbeck's PTSD Drug Fails to Win US FDA Panel Support
Otsuka Pharmaceutical Co. 's medicine for post-traumatic stress disorder with partner H. Lundbeck A/S failed to win the backing of US regulatory advisers, a major setback in the drugmakers' bid to bring the first new drug for the condition to market in more than two decades. The panel of external advisers to the Food and Drug Administration voted 10-to-1 on Friday that the efficacy of the companies' brexpiprazole tablets marketed under the brand name Rexulti — in combination with sertraline — hadn't been established.
